<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01711567</url>
  </required_header>
  <id_info>
    <org_study_id>STEEP study</org_study_id>
    <nct_id>NCT01711567</nct_id>
  </id_info>
  <brief_title>Tenofovir Disoproxil Fumarate vs. Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response to Entecavir</brief_title>
  <acronym>STEEP</acronym>
  <official_title>Switching to Tenofovir Disoproxil Fumarate vs. Continuing Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response During Entecavir Therapy: STEEP Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Entecavir, a potent antiviral agent, has been widely used for treatment-naïve chronic&#xD;
      hepatitis B patients. However, about 20% of patients showed partial virologic response after&#xD;
      2 year of entecavir therapy (33% in HBeAg positive, 10% in HBeAg negative patients).&#xD;
      Tenofovir is a nucleotide analogue with more potent antiviral activity. In addition, there is&#xD;
      no cross resistance between the two drugs. Therefore it is assumed that tenofovir would be&#xD;
      effective in the treatment of chronic hepatitis B patients who shows partial virologic&#xD;
      response (detectable HBV DNA by real time PCR after 12 months of treatment) despite treatment&#xD;
      with entecavir. In this study, we will compare the efficacy of switching to tenofovir with&#xD;
      continuing entecavir in patients who shows partial virologic response to entecavir.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The number of patients needed was calculated using PASS 2008. We hypothesized that two-thirds&#xD;
      (65%) of the patients receiving TDF, and one-fifth (20%) of the patients receiving ETV, would&#xD;
      achieve virologic response. We also assumed a 15% drop-out rate; thus, 22 patients were&#xD;
      needed in each group to achieve 80% power to demonstrate a difference between the groups with&#xD;
      a 5% level of significance.&#xD;
&#xD;
      The primary efficacy end point will be analyzed on a per-protocol basis, including only those&#xD;
      patients who had completed the treatment schedule of study. In contrast, the&#xD;
      intention-to-treat analysis will include all randomized subjects, even those dropped-out from&#xD;
      the study before 12 months, as cases of treatment failure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virologic response rate at year 1 (12 months) (HBV DNA &lt; 20 IU/mL)</measure>
    <time_frame>up to the end of year 1 (12 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>-Degree of HBV DNA reduction, mean HBV DNA, biochemical and serologic response rates, resistance, and adverse events at year 1</measure>
    <time_frame>up to the end of year 1 (12 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>entecavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard drugs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tenofovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>study drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir</intervention_name>
    <description>tenofovir 300 mg qd</description>
    <arm_group_label>tenofovir</arm_group_label>
    <other_name>tenofovir (viread)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>entecavir</intervention_name>
    <description>entecavir 0.5 mg qd</description>
    <arm_group_label>entecavir</arm_group_label>
    <other_name>entecavir(baraclude) 0.5 mg qd</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. CHB patients (positive HBsAg more than 6 months)&#xD;
&#xD;
          2. Age 19 years old&#xD;
&#xD;
          3. HBeAg positive or negative patients&#xD;
&#xD;
          4. Patients receiving entecavir 0.5 mg more than 12 months&#xD;
&#xD;
          5. Detectable HBV DNA by real time PCR (HBV &gt; 60 IU/mL)&#xD;
&#xD;
          6. Compensated liver function (Child-Pugh-Turcotte score ≤7, prothrombin time 3 sec above&#xD;
             ULN or INR ≤1.5, serum albumin &gt;3 g/dL, total bilirubin &lt;2.5 mg/dL, no history of&#xD;
             variceal bleeding, diuretics or ascites requiring paracentesis, hepatic&#xD;
             encephalopathy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of treatment with nucleotide analogue other than 0.5 mg of ETV&#xD;
&#xD;
          2. Serum creatinine level &gt; 1.5 mg/dL or creatinine clearance &lt; 50 mL/min&#xD;
&#xD;
          3. Absolute neutrophil count ≤ 1000 cell/mL&#xD;
&#xD;
          4. Hemoglobin level ≤ 10 g/dL in men or ≤ 9 g/dL in women&#xD;
&#xD;
          5. Antiviral resistance mutations on rtT184, rtS202, or rtM250 + rtM204V/I&#xD;
&#xD;
          6. A positive antibody test for human immunodeficiency virus, hepatitis C virus, or&#xD;
             hepatitis D virus&#xD;
&#xD;
          7. Pregnancy or lactation&#xD;
&#xD;
          8. HCC (in cases where alfa-fetoprotein levels were over 100 ng/mL, abdominal computed&#xD;
             tomography or magnetic resonance image was performed to exclude HCC)&#xD;
&#xD;
          9. Untreated malignancy other than HCC.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyung Joon Yim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <state>Gyeonggi-do</state>
        <zip>425-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>October 17, 2012</study_first_submitted>
  <study_first_submitted_qc>October 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2012</study_first_posted>
  <last_update_submitted>November 8, 2016</last_update_submitted>
  <last_update_submitted_qc>November 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University</investigator_affiliation>
    <investigator_full_name>Hyung Joon Yim</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Chronic Hepatitis B</keyword>
  <keyword>TENOFOVIR</keyword>
  <keyword>ENTECAVIR</keyword>
  <keyword>PARTIAL RESPONDER</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

